A Study of LY3337641 in Rheumatoid Arthritis



Status:Terminated
Conditions:Arthritis, Rheumatoid Arthritis
Therapuetic Areas:Rheumatology
Healthy:No
Age Range:18 - 65
Updated:8/29/2018
Start Date:August 22, 2016
End Date:August 15, 2018

Use our guide to learn which trials are right for you!

A Randomized, Double-Blind, Placebo-Controlled, 2-Part Phase 2 Study to Evaluate the Safety and Efficacy of LY3337641 in Adult Subjects With Rheumatoid Arthritis: The RAjuvenate Study

The main purpose of this study is to evaluate the safety and effectiveness of LY3337641 in
adults with rheumatoid arthritis (RA).


Inclusion Criteria:

- Female subjects of childbearing potential test negative for pregnancy at screening and
agree not to breastfeed

- Female subjects: agree to use a reliable method of birth control from the start of
screening until 28 days after the last dose of study drug or be of nonchildbearing
potential

- Male subjects: agree to use a reliable method of birth control from the start of
screening until 2 weeks after the last dose of study drug or have undergone vasectomy

- Have a diagnosis of RA based on the 2010 ACR/European League against Rheumatism
criteria

- Have at least 1 of the following:

- rheumatoid factor or anti-citrullinated peptide antibodies (ACPA) at screening OR

- radiographs documenting bony erosions

- Have active RA, defined as:

- Part A: ≥3 swollen joints (based on 66-joint counts)

- Part B:

- ≥6 swollen joints (based on 66-joint counts)

- ≥6 tender joints (based on 68-joint counts)

- hsCRP levels greater than the upper limit of normal (ULN) OR positive for ACPA

- Part B only: Have had inadequate response, loss of response, or intolerance to at
least 1 synthetic OR biologic disease-modifying antirheumatic drug (DMARD)

Exclusion Criteria:

- Have received any of the following:

- Part B only: any prior treatment with a product directly targeting Bruton's
tyrosine kinase (BTK) (marketed or investigational)

- belimumab, natalizumab, or vedolizumab within 6 months prior to baseline

- B-cell-depleting agents (such as rituximab) or other cell-depleting biologics
(eg, anti-CD3 antibody) within 12 months prior to screening for Part A or at any
time prior to screening for Part B

- Have known hypogammaglobulinemia

- Have hepatitis C virus, hepatitis B virus or human immunodeficiency virus

- Have active tuberculosis (TB)

- Are at high risk of infection or have recent evidence of clinically significant
infection

- Have had lymphoma, leukemia, or any malignancy within the previous 5 years except for
treated basal cell or squamous epithelial carcinomas of the skin

- Have received a live (attenuated) vaccine within 28 days prior to baseline or plan to
receive one during the study
We found this trial at
16
sites
?
mi
from
Buenos Aires,
Click here to add this to my saved trials
Clearwater, Florida 33756
Principal Investigator: Miguel Trevino
Phone: 727-584-6368
?
mi
from
Clearwater, FL
Click here to add this to my saved trials
Denver, Colorado 80230
Principal Investigator: Christopher Antolini
Phone: 303-394-2828
?
mi
from
Denver, CO
Click here to add this to my saved trials
Elizabethtown, Kentucky 42701
Principal Investigator: Daksha Mehta
Phone: 270-769-2535
?
mi
from
Elizabethtown, KY
Click here to add this to my saved trials
Franklin, Wisconsin 53132
Principal Investigator: Alvin Wells
Phone: 414-435-0025
?
mi
from
Franklin, WI
Click here to add this to my saved trials
3725 East League City Parkway
League City, Texas 77573
?
mi
from
League City, TX
Click here to add this to my saved trials
Naples, Florida 34102
Principal Investigator: Jeffrey Alper
Phone: 239-262-1745
?
mi
from
Naples, FL
Click here to add this to my saved trials
Nassau Bay, Texas 77058
Principal Investigator: Prashanth Sunkureddi
Phone: 713-677-0086
?
mi
from
Nassau Bay, TX
Click here to add this to my saved trials
New Port Richey, Florida 34652
Principal Investigator: Farrukh Zaidi
Phone: 727-849-4131
?
mi
from
New Port Richey, FL
Click here to add this to my saved trials
North Charleston, South Carolina 29406
?
mi
from
North Charleston, SC
Click here to add this to my saved trials
Palm Desert, California 92260
Principal Investigator: Maria Greenwald
Phone: 760-341-6800
?
mi
from
Palm Desert, CA
Click here to add this to my saved trials
Palo Alto, California 94305
Principal Investigator: Mark Genovese
Phone: 650-498-4528
?
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Saint Louis, Missouri 63117
Principal Investigator: John Budd
Phone: 314-646-0688
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Salisbury, North Carolina 28144
Principal Investigator: Rakesh Patel
Phone: 704-647-9913
?
mi
from
Salisbury, NC
Click here to add this to my saved trials
Venice, Florida
Principal Investigator: Jeffrey Kaine
Phone: 941-485-8314
?
mi
from
Venice, FL
Click here to add this to my saved trials
1907 Tradd Ct
Wilmington, North Carolina 28401
(910) 799-5500
PMG Research of Wilmington PMG Research of Wilmington has two offices situated in a 1...
?
mi
from
Wilmington, NC
Click here to add this to my saved trials